CL2014001663A1 - Metodo para tratar una enfermedad desmielinizante tal como esclerosis multiple que comprende administrar compuestos andrografolidos y una interferona; y su uso para tratar una enfermedad desmielinizante tal como esclerosis multiple. - Google Patents

Metodo para tratar una enfermedad desmielinizante tal como esclerosis multiple que comprende administrar compuestos andrografolidos y una interferona; y su uso para tratar una enfermedad desmielinizante tal como esclerosis multiple.

Info

Publication number
CL2014001663A1
CL2014001663A1 CL2014001663A CL2014001663A CL2014001663A1 CL 2014001663 A1 CL2014001663 A1 CL 2014001663A1 CL 2014001663 A CL2014001663 A CL 2014001663A CL 2014001663 A CL2014001663 A CL 2014001663A CL 2014001663 A1 CL2014001663 A1 CL 2014001663A1
Authority
CL
Chile
Prior art keywords
multiple sclerosis
demyelinating disease
interferon
administering
treat
Prior art date
Application number
CL2014001663A
Other languages
English (en)
Spanish (es)
Inventor
Orozco Juan L Hancke
Rafael Burgos
Original Assignee
Innobioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001663(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innobioscience Llc filed Critical Innobioscience Llc
Publication of CL2014001663A1 publication Critical patent/CL2014001663A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2014001663A 2011-12-21 2014-06-20 Metodo para tratar una enfermedad desmielinizante tal como esclerosis multiple que comprende administrar compuestos andrografolidos y una interferona; y su uso para tratar una enfermedad desmielinizante tal como esclerosis multiple. CL2014001663A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161578650P 2011-12-21 2011-12-21

Publications (1)

Publication Number Publication Date
CL2014001663A1 true CL2014001663A1 (es) 2015-02-27

Family

ID=48669439

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001663A CL2014001663A1 (es) 2011-12-21 2014-06-20 Metodo para tratar una enfermedad desmielinizante tal como esclerosis multiple que comprende administrar compuestos andrografolidos y una interferona; y su uso para tratar una enfermedad desmielinizante tal como esclerosis multiple.

Country Status (10)

Country Link
US (1) US9060994B2 (https=)
EP (1) EP2670406B1 (https=)
JP (1) JP5936707B2 (https=)
AU (1) AU2012359081B2 (https=)
BR (1) BR112014015178A2 (https=)
CA (1) CA2853779C (https=)
CL (1) CL2014001663A1 (https=)
ES (1) ES2554459T3 (https=)
RU (1) RU2014113967A (https=)
WO (1) WO2013096423A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214346A1 (en) * 2016-06-08 2017-12-14 Innobiosciences, Llc Andrographolide treats progressive forms of multiple sclerosis
US11318153B2 (en) 2018-06-25 2022-05-03 Bialpha International Sdn. Bhd. Method of using Neoandrographolide for lowering blood sugar, lowering blood lipid, improving liver function and improving renal function
CN109824655B (zh) * 2019-04-08 2021-09-24 沈阳药科大学 穿心莲内酯化合物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043027A1 (en) * 1999-04-08 2000-10-11 Applied Research Systems ARS Holding N.V. Treatment of multiple sclerosis with a combination of Interferon and Growth hormone
US6410590B1 (en) 2000-02-03 2002-06-25 Dr. Reddy's Research Foundation Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them
US20050181033A1 (en) * 2000-06-29 2005-08-18 Dekker John P.Iii Method for delivering interferons to the intradermal compartment
WO2003025541A2 (en) * 2001-09-18 2003-03-27 Chiron Corporation Methods for treating multiple sclerosis
CN1921872A (zh) * 2004-02-03 2007-02-28 智利南方大学 用于激活PPR－γ受体而治疗自身免疫性疾病和阿尔茨海默病的提取自穿心莲的半日花烷型二萜类组合物
US20050220764A1 (en) 2004-04-01 2005-10-06 Schering Aktiengesellschaft Higher-doses of interferon-beta for treatment of multiple sclerosis
US20080108641A1 (en) 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
KR20120098578A (ko) 2009-06-22 2012-09-05 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법

Also Published As

Publication number Publication date
RU2014113967A (ru) 2016-02-10
CA2853779C (en) 2016-04-26
NZ625051A (en) 2016-07-29
EP2670406A4 (en) 2014-05-28
EP2670406B1 (en) 2015-09-02
AU2012359081A1 (en) 2014-06-05
AU2012359081B2 (en) 2015-09-17
JP5936707B2 (ja) 2016-06-22
BR112014015178A2 (pt) 2017-06-13
US9060994B2 (en) 2015-06-23
WO2013096423A1 (en) 2013-06-27
US20140301981A1 (en) 2014-10-09
EP2670406A1 (en) 2013-12-11
ES2554459T3 (es) 2015-12-21
CA2853779A1 (en) 2013-06-27
JP2015500880A (ja) 2015-01-08

Similar Documents

Publication Publication Date Title
CL2013003358A1 (es) Uso de un fumarato para preparar un medicamento útil para tratar esclerosis múltiple.
BR112015002541A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
CL2013002612A1 (es) Compuestos derivados de c4-monometil triterpenoides; composicion farmaceutica que los comprende; y metodo para tratar o prevenir una enfermedad o un trastorno.
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
BR112014010460A2 (pt) composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
BR112014006324A2 (pt) método para tratar hcv
CL2014000428A1 (es) Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica.
IL232222B (en) A cd20 antibody for use as a medicament for treating multiple sclerosis
BR112014010391A2 (pt) composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
BR112014004103A2 (pt) auto-injetor para seringa previamente preenchida retrátil
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
CL2013001428A1 (es) Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.
CL2011003120A1 (es) Alimento medico que comprende glicomacropeptido y dos o mas aminoacidos suplementarios; metodo para fabricar dicho alimento medico; y su uso para tratar un desorden metabolico.
CL2014000470A1 (es) Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana.
BR112012026843A2 (pt) composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
ECSP14013239A (es) Composiciones farmacéuticas
BR112012026570A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
BR112014010545A2 (pt) composição farmacêutica, método para tratar um paciente infectado com vírus da hepatite c, uso de uma composição
BR112014002830A2 (pt) fotossensibilizador para uso terapêutico
BR112015008113A2 (pt) novo processo para preparar compostos para uso no tratamento de câncer.
BR112014013694A2 (pt) método para tratar uma doença, e, kit
CL2015000967A1 (es) Método para mejorar la tolerancia al estrés abiótico en plantas usando un compuesto derivado de carboxamida o tiocarboxamida; y uso de dicho compuesto.
CL2014000172A1 (es) Composicion en spray que comprende a) un portador de oxigeno, tal como hemoglobina o mioglobina; y b) al menos un ingrediente adicional; metodo para preparar la composicion; proceso para purificar un portador de oxigeno; y su uso para el tratamiento externo de heridas.
CL2014000671A1 (es) Composicion farmaceutica que comprende rifabutina, claritromicina y clofazimina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple y sus sintomas asociados, tiroiditis de hashimoto y sindrome de melkersson o sarcoidosis.